103
Participants
Start Date
April 16, 2018
Primary Completion Date
April 21, 2021
Study Completion Date
April 21, 2021
AK1820
"Only a switch from IV infusion (vial) to oral administration (capsule) will be permitted; a switch from oral administration to IV infusion will not be possible.~372.6 mg of AK1820 (isavuconazonium sulfate) is equivalent to 200 mg of isavuconazole.~Other Names: Cresemba, BAL8557"
Voriconazole
"Only a switch from IV infusion (vial) to oral administration (tablet) will be permitted; a switch from oral administration to IV infusion will not be possible.~Other Name : VFend"
Research site, Nagakute
Research site, Nagoya
Research site, Seto
Research site, Higashiku
Research site, Minamiku
Research site, Nagara
Research site, Naka-Ku
Research site, Asahikawa
Research site, Kawasaki
Research site, Yokohama
Research site, Chuo-Ku
Research site, Tsu
Research site, Isahaya
Research site, Ōmura
Research site, Sasebo
Research site, Tenri
Research site, Yufu
Research site, Kurashiki
Research site, Nakagami
Research site, Abeno-Ku
Research site, Sakai
Research site, Ōmiya
Research site, Hamamatsu
Research site, Shimotsuke
Research site, Kiyose
Research site, Minato-Ku
Research site, Mitaka
Research site, Ōta-ku
Research site, Shinagawa-Ku
Research site, Shinjuku-Ku
Research site, Chiba
Research site, Ibaraki
Research site, Nagasaki
Asahi Kasei Pharma Corporation
INDUSTRY